IL151097A0 - Tumour-specific animal proteins - Google Patents

Tumour-specific animal proteins

Info

Publication number
IL151097A0
IL151097A0 IL15109701A IL15109701A IL151097A0 IL 151097 A0 IL151097 A0 IL 151097A0 IL 15109701 A IL15109701 A IL 15109701A IL 15109701 A IL15109701 A IL 15109701A IL 151097 A0 IL151097 A0 IL 151097A0
Authority
IL
Israel
Prior art keywords
tumour
animal proteins
specific animal
polypeptides
polynucleotides
Prior art date
Application number
IL15109701A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0004269A external-priority patent/GB0004269D0/en
Priority claimed from GB0009905A external-priority patent/GB0009905D0/en
Priority claimed from GB0021080A external-priority patent/GB0021080D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of IL151097A0 publication Critical patent/IL151097A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15109701A 2000-02-23 2001-02-16 Tumour-specific animal proteins IL151097A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0004269A GB0004269D0 (en) 2000-02-23 2000-02-23 Novel compounds
GB0009905A GB0009905D0 (en) 2000-04-20 2000-04-20 Novel compounds
GB0021080A GB0021080D0 (en) 2000-08-25 2000-08-25 Novel compounds
PCT/EP2001/001779 WO2001062778A2 (en) 2000-02-23 2001-02-16 Tumour-specific animal proteins

Publications (1)

Publication Number Publication Date
IL151097A0 true IL151097A0 (en) 2003-04-10

Family

ID=27255552

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15109701A IL151097A0 (en) 2000-02-23 2001-02-16 Tumour-specific animal proteins
IL151097A IL151097A (en) 2000-02-23 2002-08-06 An immunogenic preparation comprising CASB7439 polypeptide and its use in the manufacture of a vaccine for the treatment of diseases related to the colon

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL151097A IL151097A (en) 2000-02-23 2002-08-06 An immunogenic preparation comprising CASB7439 polypeptide and its use in the manufacture of a vaccine for the treatment of diseases related to the colon

Country Status (24)

Country Link
US (5) US20030157118A1 (no)
EP (2) EP1265915B1 (no)
JP (1) JP5502253B2 (no)
KR (3) KR100919916B1 (no)
CN (1) CN1254541C (no)
AT (1) ATE487733T1 (no)
AU (3) AU5615601A (no)
BR (1) BR0108654A (no)
CA (1) CA2400842C (no)
CY (2) CY1111156T1 (no)
CZ (1) CZ303468B6 (no)
DE (1) DE60143425D1 (no)
DK (2) DK1265915T3 (no)
ES (1) ES2389445T3 (no)
HK (2) HK1052710A1 (no)
HU (1) HUP0300054A3 (no)
IL (2) IL151097A0 (no)
MX (1) MXPA02008279A (no)
NO (1) NO332141B1 (no)
NZ (1) NZ520673A (no)
PL (1) PL209127B1 (no)
PT (2) PT1265915E (no)
SI (2) SI1265915T1 (no)
WO (1) WO2001062778A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1265915T3 (da) * 2000-02-23 2011-02-14 Glaxosmithkline Biolog Sa Nye forbindelser
PT2266603E (pt) * 2000-10-18 2012-11-02 Glaxosmithkline Biolog Sa Vacinas tumorais
WO2002061085A2 (en) 2000-10-31 2002-08-08 Ryan James W Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
GB0100756D0 (en) 2001-01-11 2001-02-21 Powderject Res Ltd Needleless syringe
GB0111974D0 (en) * 2001-05-16 2001-07-04 Glaxosmithkline Biolog Sa Novel Compounds
KR20050057047A (ko) * 2002-08-29 2005-06-16 제넨테크, 인크. 아캐트-스큐트 유사-2 폴리펩티드 및 코딩 핵산 및 종양의진단 및 치료 방법
CN1310033C (zh) * 2004-03-23 2007-04-11 中国医学科学院肿瘤医院肿瘤研究所 一种检测血清蛋白指纹的新方法
US20100021424A1 (en) 2006-06-02 2010-01-28 Vincent Brichard Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy
GB0708758D0 (en) 2007-05-04 2007-06-13 Powderject Res Ltd Particle cassettes and process thereof
US20090035360A1 (en) 2007-05-24 2009-02-05 Dominique Ingrid Lemoine Lyophilised antigen composition
US8916514B2 (en) * 2009-05-27 2014-12-23 Glaxosmithkline Biologicals, S.A. CASB7439 constructs
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
WO2011066505A2 (en) * 2009-11-30 2011-06-03 Pathak Holdings Llc Methods and compositions for filling fleshy fruits and vegetables
RS57350B1 (sr) * 2011-10-03 2018-08-31 Mx Adjuvac Ab Nanočestice, postupak dobijanja i njihova primena kao nosača amfipatičnih ili hidrofobnih molekula u medicini, uključujući i terapiju kancera, kao i prehrambenih jedinjenja
GB201520592D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US10422675B2 (en) 2017-06-09 2019-09-24 Aps Technology, Inc. System and method for monitoring mud flow in a component of drilling system

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE10399031I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
CA2050911C (en) 1989-05-04 1997-07-15 Thomas R. Tice Encapsulation process and products therefrom
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
WO1991002805A2 (en) 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE69031951T2 (de) 1989-11-16 1998-08-13 Cornell Res Foundation Inc Transformation von tierischen Hautzellen mit hilfe von Partikeln
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
GB9022190D0 (en) 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
WO1993015763A1 (en) * 1992-02-18 1993-08-19 Smithkline Beecham Corporation Vaccinal polypeptides
DE69312487T2 (de) 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ES2131676T3 (es) 1993-01-11 1999-08-01 Dana Farber Cancer Inst Inc Induccion de respuestas con linfocitos t citotoxicos.
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
CA2160011A1 (en) 1993-04-06 1994-10-13 Philip D. Greenberg Chimeric cytokine receptors in lymphocytes
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
JPH08508889A (ja) 1993-06-07 1996-09-24 アムジエン・インコーポレーテツド ハイブリッドレセプター分子
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AU8116494A (en) 1993-11-12 1995-06-13 Kenichi Matsubara Gene signature
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0690732T3 (da) 1994-01-21 2003-05-19 Powderject Vaccines Inc Gasdrevet genindførselsinstrument
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
BR9707400A (pt) * 1996-02-09 2000-01-04 Smithkline Beecham Biolog Vacinas contra produto do gene 63 de vìrus varicella zoster.
US5776683A (en) 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
WO1999040188A2 (en) * 1998-02-05 1999-08-12 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations
TR200002338T2 (tr) 1998-02-12 2002-06-21 Immune Complex Corporation Stratejik olarak yenilenmiş hepatit B çekirdek proteinler.
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP1064025B1 (en) * 1998-03-09 2006-09-13 GlaxoSmithKline Biologicals S.A. Combined vaccine compositions
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
DE69929444T2 (de) 1998-08-10 2006-09-28 Antigenics Inc., Woburn Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
US6087168A (en) * 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
HUP0200366A2 (en) * 1999-03-11 2002-06-29 Smithkline Beecham Biolog Novel compounds
AU5788900A (en) 1999-07-07 2001-01-22 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
US20020081590A1 (en) 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
DK1265915T3 (da) * 2000-02-23 2011-02-14 Glaxosmithkline Biolog Sa Nye forbindelser
US7811574B2 (en) * 2000-02-23 2010-10-12 Glaxosmithkline Biologicals S.A. Tumour-specific animal proteins
WO2002061085A2 (en) * 2000-10-31 2002-08-08 Ryan James W Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
KR20050057047A (ko) 2002-08-29 2005-06-16 제넨테크, 인크. 아캐트-스큐트 유사-2 폴리펩티드 및 코딩 핵산 및 종양의진단 및 치료 방법
US8916514B2 (en) 2009-05-27 2014-12-23 Glaxosmithkline Biologicals, S.A. CASB7439 constructs

Also Published As

Publication number Publication date
DE60143425D1 (de) 2010-12-23
ES2389445T3 (es) 2012-10-26
CY1111156T1 (el) 2015-06-11
NO20024002L (no) 2002-10-22
BR0108654A (pt) 2003-04-29
EP1265915B1 (en) 2010-11-10
US8535690B2 (en) 2013-09-17
US20060171953A1 (en) 2006-08-03
KR20090085697A (ko) 2009-08-07
NO332141B1 (no) 2012-07-02
EP1650221B1 (en) 2012-06-27
NZ520673A (en) 2004-09-24
CZ20022874A3 (cs) 2003-02-12
EP1650221A3 (en) 2006-12-20
CN1426421A (zh) 2003-06-25
SI1650221T1 (sl) 2012-09-28
CZ303468B6 (cs) 2012-10-03
US7803379B2 (en) 2010-09-28
KR20080029007A (ko) 2008-04-02
WO2001062778A3 (en) 2002-04-04
AU2001256156B2 (en) 2006-01-05
US20030157118A1 (en) 2003-08-21
NO20024002D0 (no) 2002-08-22
ATE487733T1 (de) 2010-11-15
EP1650221A2 (en) 2006-04-26
JP5502253B2 (ja) 2014-05-28
DK1650221T3 (da) 2012-09-03
SI1265915T1 (sl) 2011-02-28
DK1265915T3 (da) 2011-02-14
CA2400842C (en) 2013-01-15
PL362698A1 (en) 2004-11-02
AU2006201042A1 (en) 2006-03-30
US8207123B2 (en) 2012-06-26
KR20020079887A (ko) 2002-10-19
US20120244175A1 (en) 2012-09-27
HK1052710A1 (en) 2003-09-26
CN1254541C (zh) 2006-05-03
CY1113109T1 (el) 2016-04-13
HUP0300054A1 (hu) 2003-05-28
MXPA02008279A (es) 2002-11-29
AU2006201042B2 (en) 2009-10-08
EP1265915A2 (en) 2002-12-18
US20100291121A1 (en) 2010-11-18
PL209127B1 (pl) 2011-07-29
AU5615601A (en) 2001-09-03
WO2001062778A2 (en) 2001-08-30
HUP0300054A3 (en) 2012-09-28
US20110052615A1 (en) 2011-03-03
JP2003530088A (ja) 2003-10-14
CA2400842A1 (en) 2001-08-30
HK1093513A1 (en) 2007-03-02
PT1265915E (pt) 2011-02-07
KR100919916B1 (ko) 2009-10-07
PT1650221E (pt) 2012-09-05
IL151097A (en) 2012-05-31
KR100848973B1 (ko) 2008-07-30

Similar Documents

Publication Publication Date Title
IL151097A0 (en) Tumour-specific animal proteins
PL354143A1 (en) Novel uses
CY1108280T1 (el) Basb205 πολυπεπτιδια και πολυνουκλεοτιδια που τα κωδικοποιουν
NZ513838A (en) Novel compounds
DK1163343T3 (da) Neisseria meningitidis antigene polypeptider, tilsvarende polynukleotider og beskyttende antistoffer
WO2000058460A3 (en) Casb619 involved in colon cancers
ATE281524T1 (de) Moraxella catarrhalis pilq proteine
WO2001023417A3 (en) Human tumor-associated lak-4p related polynucleotides and polypeptides and their uses
WO2000043509A3 (en) Polynucleotides and their applications in diagnostics
PT1204752E (pt) Polipéptidos imunogénicos derivados de moraxella catarrhalis e suas utilizações
WO2002024729A3 (en) Haemophilus influenzae basb202 polypeptide, production, vaccine and diagnostic use
ATE515511T1 (de) Nicht-typisierbare haemophilus influenzae basb201 polypeptide und polynukleotide und deren verwendungen
WO2001034795A3 (en) Casb7435 polypeptide, nucleic acid encoding it, and their uses in treatment and diagnosis
ATE293693T1 (de) Moraxella catarrhalis antigen basb117
CY1108790T1 (el) Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου
WO2002032945A3 (en) Haemophilus influenzae basb206 gene and protein
ATE293692T1 (de) Moraxella catarrhalis antigen basb120
WO2001075001A3 (fr) Nouveau polypeptide, protéine kinase humaine dépendant de l'adénosine cyclique 9, et poynucléotide codant pour ce polypeptide